Valuation: Caplin Point Laboratories Limited

Market Cap 190B 2.03B 1.82B 1.68B 1.52B 2.88B 2.96B 20.07B 7.99B 102B 7.61B 7.45B 322B P/E 2027 *
26.2x
P/E 2028 * 22.6x
Enterprise Value 190B 2.03B 1.82B 1.68B 1.52B 2.88B 2.96B 20.07B 7.99B 102B 7.61B 7.45B 322B EV / Sales 2027 *
7.58x
EV / Sales 2028 * 6.71x
Free-Float
26.56%
Yield 2027 *
0.16%
Yield 2028 * 0.16%
1 day+0.80%
1 week+6.73%
Current month+8.43%
1 month+2.50%
3 months-3.85%
6 months+35.73%
Current year+36.92%
1 week 2,362
Extreme 2362
2,595.5
1 month 2,177
Extreme 2177
2,595.5
Current year 1,502.45
Extreme 1502.45
2,990.6
1 year 1,502.45
Extreme 1502.45
2,990.6
3 years 1,179.95
Extreme 1179.95
2,990.6
5 years 575
Extreme 575
2,990.6
10 years 180
Extreme 180
2,990.6
Manager TitleAgeSince
Chief Executive Officer 71 28/03/2015
Director of Finance/CFO - 19/02/2016
Chief Administrative Officer - -
Director TitleAgeSince
Chairman 73 27/01/2010
Director/Board Member - 05/11/2025
Director/Board Member 71 28/03/2015
Change 5-day change 1-year change 3-year change Capi.($)
+0.80%+6.73%+29.69%+110.39% 2.03B
-1.01%+0.25%+43.78%+132.00% 1,276B
-1.42%+0.45%+43.19%+88.00% 676B
-1.33%-1.38%+29.12%+109.72% 519B
-0.58%+1.01%+38.52%+67.50% 388B
-1.74%-3.03%+60.31%+42.29% 365B
-1.40%-1.15%+27.52%+56.84% 307B
-0.28%-1.11%+2.99%+35.32% 287B
-0.96%-3.39%+36.58%+73.32% 252B
-0.90%-2.64%+38.61%+126.72% 212B
Average -0.89%+2.80%+35.03%+84.21% 428B
Weighted average by Cap. -1.12%+2.51%+38.26%+93.28%

Financials

2027 *2028 *
Net sales 25.07B 267M 240M 221M 201M 380M 390M 2.65B 1.05B 13.43B 1B 982M 42.47B 28.34B 302M 271M 250M 227M 429M 441M 2.99B 1.19B 15.18B 1.13B 1.11B 48B
Net income 7.26B 77.48M 69.48M 64.04M 58.16M 110M 113M 767M 305M 3.89B 291M 285M 12.3B 8.41B 89.71M 80.45M 74.14M 67.33M 127M 131M 888M 354M 4.51B 337M 330M 14.25B
Net Debt - -
Projected Income Statement - Annual - Caplin Point Laboratories Limited
Logo Caplin Point Laboratories Limited
Caplin Point Laboratories Limited is an India-based pharmaceutical company with a business model catering predominantly to emerging markets of Latin America and Africa. The Company has also entered regulated markets such as the United States through its Subsidiary, Caplin Steriles Limited. The Company's operations include research & development and manufacturing of finished formulations, active pharmaceutical ingredients (APIs), clinical research, front-end generic presence in Latin America, brand marketing in Francophone Africa and a USFDA/EU-GMP approved injectable facility. In the Regulated Markets, its products include liquid & lyophilized vials, pre-filled syringes, three-pc ophthalmic droppers and pre-mix bags. In the Emerging Markets, its products include tablets, dry syrups - bottles, soft gels, capsules, suppositories, liquid syrups - bottles, liquid injectables in ampoules & vials, lyophilized vials, prefilled syringes (PFS), and emulsion injection in ampoules & vials.
Employees
4,199
Date Price Change Volume
11/11/26 ₹2,520.95 +0.80% 4,703
09/11/26 ₹2,501.05 +2.10% 14,212
08/11/26 ₹2,449.70 +2.87% 1,519
06/11/26 ₹2,381.35 -1.70% 4,765
05/11/26 ₹2,422.55 +0.27% 5,740
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Caplin Point Laboratories Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2,501.05INR
Average target price
2,765.00INR
Spread / Average Target
+10.55%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Caplin Point Laboratories Limited
  1. Stock Market
  2. Stocks
  3. CAPLIPOINT Stock